AstraZeneca

AZN · NYSE · USD

$156.82−0.56%−$0.88

Close · October 2, 2026

At a glance

Revenue growth: +8.63%; 2025 vs 2024
Net income growth: +45.34%; 2025 vs 2024
Net margin: 17.4%; 2024: 13.0%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Annual
Item	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Total revenue	58,739	54,073	45,811	44,351	37,417	26,617	24,384	22,090	22,465	23,002
Cost of revenue	10,746	9,638	8,045	8,641	12,005	5,246	4,848	4,504	4,137	3,996
Gross profit	47,993	44,435	37,766	35,710	25,412	21,371	19,536	17,586	18,328	19,006
Selling, general and administrative	20,072	19,453	18,036	17,460	14,673	11,586	11,438	10,822	9,406	9,743
Research and development	13,851	12,243	10,306	9,669	8,049	5,901	5,349	5,299	5,455	5,679
Operating income	14,292	12,929	9,699	8,812	2,897	4,370	3,068	1,731	3,686	3,906
EBIT	14,292	12,929	9,699	8,812	2,897	4,370	3,068	1,731	3,686	3,906
EBITDA	19,280	17,567	14,275	13,744	6,701	6,990	5,575	4,462	6,006	6,087
Interest expense	1,365	1,403	1,219	917	776	738	780	744	664	617
Pre-tax income	12,402	8,691	6,899	2,501	-265	3,916	1,548	1,993	2,227	3,552
Income tax	2,169	1,650	938	-792	-380	772	321	-57.0	-641	146
Net income	10,225	7,035	5,955	3,288	112	3,196	1,335	2,155	3,001	3,499
Net income to common shareholders	10,225	7,035	5,955	3,288	112	3,196	1,335	2,155	3,001	3,499
Basic EPS	6.60	4.54	3.84	2.12	0.08	2.44	1.03	1.70	2.37	2.77
Diluted EPS	6.54	4.50	3.81	2.11	0.08	2.44	1.03	1.70	2.37	2.76
Average shares (basic)	1,550	1,550	1,549	1,548	1,418	1,312	1,301	1,267	1,266	1,265
Average shares (diluted)	1,562	1,563	1,562	1,560	1,427	1,313	1,301	1,267	1,267	1,266
Dividend per share	3.20	3.10	2.90	2.90	2.87	2.80	2.80	2.80	2.80	2.80